A one-time injection, aimed at the diseases nobody calls rare
Gene therapy spent two decades earning its reputation on diseases that touch a few thousand people at a time. Beautiful science, narrow reach, prices that read like phone numbers. Shankar Ramaswamy looked at that and asked the uncomfortable question: why stop there? At Kriya Therapeutics, the company he co-founded in 2019 and still runs as chairman and CEO, the target list is deliberately unglamorous - geographic atrophy, thyroid eye disease, type 1 diabetes, metabolic conditions, a clutch of neurology programs. Common diseases. Millions of patients. One dose meant to last.
It is a contrarian bet dressed as an obvious one. The obvious part: if a single administration can produce a durable therapeutic protein inside the body, you have changed the economics of chronic disease. The contrarian part: doing it at a scale, cost and manufacturing quality that the field has mostly treated as a someday problem. Ramaswamy treats it as a today problem, and has spent more than $600 million convincing investors it is solvable.
We're a company focused on bringing one-time gene therapies to more common, highly prevalent diseases.- Shankar Ramaswamy
The headline figures only matter because of what sits behind them: a vertically integrated company that designs its own vectors, runs its own computational biology, and - unusually - manufactures its own gene therapies in-house. Most biotechs rent that last step. Kriya owns the factory, because Ramaswamy decided that controlling manufacturing was the difference between a science project and a product.
The money arrived in deliberate stages, each one buying a different piece of the thesis. An $80.5 million Series A bought the right to say gene therapy did not have to stop at rare disease. A $270 million Series C bought the infrastructure - the vectors, the data, the plant - to act on it. A $150 million extension and, later, a Series D pushed cumulative funding toward $1.19 billion. Investors were not buying a single molecule; they were buying a machine for producing many of them. That is a harder story to tell and a more durable one if it works.
Computation before the wet lab
Ask Ramaswamy what makes Kriya different and the answer is rarely a single hero drug. It is a way of working. The company leans on computational biology to design and optimize its vectors and therapeutic constructs before a pipette ever moves - a way of narrowing a near-infinite design space to the candidates worth building. In a field where a single manufacturing run can cost more than a house, deciding what to make is almost as important as making it well.
Pair that with in-house manufacturing and the logic closes. Design digitally, build physically, and keep both under one roof so that the lessons from the factory floor flow back into the next design. It is a loop, not a relay. That integration is the quiet reason Ramaswamy can talk about throughput and cost as engineering variables rather than acts of faith. He is not waiting for the field to hand him a cheaper process; he is trying to build one.
From evaluating other people's drugs to building the whole pipeline
The shape of the career is a steady widening of ambition. He started inside someone else's machine and ended up building his own, on his own terms.
- ~2014Joined the early foundational team at Roivant Sciences, the outfit that turned drug development into a subsidiary-spinning model. His job: find and judge pipeline candidates worth backing.
- 2015Led corporate development at Axovant Sciences, Roivant's first public subsidiary, and helped execute its IPO - over $360 million, the largest biotech IPO at the time.
- 2019Co-founded Kriya Therapeutics with industry veteran Roger Jeffs. Took the opposite structural bet from Roivant: not many thin subsidiaries, but one deep, vertically integrated company.
- 2021-22Stacked an $80.5M Series A and a $270M Series C to push gene therapy beyond rare disease. Named Triangle Business Journal Life Sciences CEO of the Year in 2022.
- 2023Named one of the Pharma Voice 100 Trailblazers shaping the future of the industry.
- 2025Extended the financing story with a Series D, pushing Kriya's cumulative funding toward $1.19 billion.
An MD who thinks like a market
Two degrees, two worlds. Ramaswamy earned his medical degree at Brown University and his undergraduate degree in economics at Harvard. The pairing is not decoration. The medicine explains why he cares about durable, single-dose treatments; the economics explains why he is obsessed with throughput, cost and the unglamorous machinery of making a therapy at scale. Plenty of founders can describe a mechanism of action. Fewer can describe it and then tell you what it costs to manufacture a million doses.
That double-vision shows up in how he talks about the field. Where some scientists describe gene therapy as a frontier of pure discovery, Ramaswamy keeps returning to engineering language - scale, throughput, quality, cost. He inherited an operating education at Roivant, learned what a public offering actually demands at Axovant, and then folded both into a company built to make gene therapy boring in the best possible way: repeatable, manufacturable, and within reach.
The technology has really matured to a point where we can take that next leap as a field to bring gene therapies into a broader universe of diseases.- Shankar Ramaswamy, on the field's inflection point
Ordinary diseases, on purpose
Read Kriya's target list and the strategy explains itself. These are not the names that win sympathy galas. They are the diseases that fill clinics.
Each one is a bet that a durable, single administration beats a lifetime of management. The harder the disease is to treat repeatedly, the more a one-time therapy is worth. That is the whole thesis, compressed.
Consider type 1 diabetes, a condition managed through constant vigilance and daily intervention. Or geographic atrophy and thyroid eye disease, where the eye is both the target and the constraint. A therapy that works once, and keeps working, would not just be a better product - it would be a different category of care. That is the line Ramaswamy keeps walking up to: not a marginally improved treatment, but a reframing of what treatment even means for diseases people currently live with rather than recover from.
The three numbers Kriya is built to move
Ramaswamy is unusually blunt about the obstacles. He names them as solvable challenges - scale, cost, throughput - and then builds the company around solving them. The bars below are directional, not audited: a sketch of where the field has been and where Kriya is trying to push it.
We as a field need to figure out how we can scale the technology, how we can bring down the cost, and how we can improve throughput and quality. But those are solvable challenges.- Shankar Ramaswamy
Things you won't find on the org chart
He owns the factory
Kriya pairs computational biology with its own GMP manufacturing. Most biotechs outsource the make step; Ramaswamy treated it as the strategic core, not a vendor relationship.
Triangle, not the coast
He runs Kriya from Morrisville, North Carolina, in the Research Triangle, sidestepping the Boston-and-Bay-Area gravity that pulls most gene therapy startups.
The opposite of his alma mater
Roivant ran on many thin subsidiaries. Kriya is one deep, integrated company. The structure is a deliberate rebuttal of the model that trained him.
A record IPO on his resume
At Axovant he helped execute a $360M+ public offering - the largest biotech IPO of its moment - before he ever ran his own company.
Doctor first
The Brown MD frames the mission. Durable, single-dose treatments aren't an abstraction to a physician who knows what chronic management costs a patient.
A family in the field
He is the brother of entrepreneur Vivek Ramaswamy, who founded Roivant - the company where Shankar got his start before striking out to build Kriya.
On the precipice
There is a pattern in how he speaks. No miracle language, no breathless promises. Just a flat conviction that the science is ready and the bottleneck is execution - and a willingness to put nine figures behind that read. The aspiration is large but stated plainly: make durable, single-dose gene therapy affordable and scalable enough to reach the millions, not the few.
It is worth sitting with how unfashionable that is. The glamour in biotech tends to cluster around the newest modality and the rarest indication. Ramaswamy went the other way - toward established diseases, in-house plumbing, and a city far from the usual headlines. If the bet pays off, the reward is not a single celebrated cure but a repeatable process that turns gene therapy from an event into an option. That is a less romantic ambition, and a far bigger one. He seems entirely comfortable with the trade.
Links & sources
Profile compiled from public sources. Facts verifiable as of June 2026; figures are approximate where noted.